Preparation of dy/ho-edtmp: a potential in vivo generator system for bone marrow ablation

Nuclear Medicine Communications

Volumn 25, Issue 6, 2004, Pages 615-621

  Pedraza López, Martha ^a   Ferro Flores, Guillermina ^a   de Murphy, Consuelo Arteaga ^b   Tendilla, Jose I ^b   Villanueva Sánchez, Octavio ^b  

^a Instituto Nacional de Ciencias Médicas y Nutrición   (United States)

^b Instituto Nacional de Investigaciones Nucleares   (United States)

Author keywords

Bone marrow ablation; Dy Ho EDTMP; Dysprosium 166; Holmium 166; in vivo generator; Targeted radiotherapy

Indexed keywords

DYSPROSIUM; ETHYLENEDIAMINE TETRAKIS(METHYLENEPHOSPHONIC ACID); HOLMIUM; LEXIDRONAM DYSPROSIUM DY 166; LEXIDRONAM HOLMIUM HO 166; LEXIDRONAM SAMARIUM SM 153; RADIOPHARMACEUTICAL AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN;

ANIMALS; BONE MARROW; BONE MARROW NEOPLASMS; DRUG STABILITY; FEASIBILITY STUDIES; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 2542570143     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000126516.57329.07     Document Type: Article

References (12)

1. Barlett ML, Webb M, Durrant S, Morton AJ, Allison R, Macfarlene DJ. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other hematological malignancies. Eur J Nucl Med 2002; 29:1470-1477.
2. Bayouth JE, Macey DJ, Kasi LP. Pharmacokinetics, dosimetry and toxicity of holmium-166 DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med 1995; 36:730-737.
3. Rajendran JG, Eary JF, Bensinger W, Durack LD, Vernon C, Fritzberg A. High-dose Ho-166-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. J Nucl Med 2002; 43:1383-1390.
4. Knapp FF, Mirzadeh S. The continuing important role of radionuclide generator systems for nuclear medicine. Eur J Nucl Med 1994; 21:1151-1165.
5. Lambrecht RM, Tomiyoshi K, Sekine T. Radionuclide generators. Radiochim Acta 1997; 77:103-123.
6. 166Ho]holmium in vivo generator. Appl Radiat Isot 1995; 46:759-764.
7. Louvinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. Revised edn. New York: Society of Nuclear Medicine; 1991.
8. Eckerman KF, Stabin MG. Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions. Health Phys 2000; 78:199-214.
9. International Commission on Radiological Protection. Basic anatomical and physiological data for use in radiological protection: the skeleton - a report of a Task Group of Committee 2 of the International Commission on Radiological Protection. Ann ICRP 1995; 25:1-80.
10. Volkert WA, Hoffman TJ. Therapeutic radiopharmaceuticals. Chem Rev 1999; 99:2269-2292.
11. 153Sm-EDTMP and factors affecting radiochemical purity and stability. J Radioanal Nucl Chem Articles 1996; 204:303-311.
12. Kassis AI, Adelstein J. Considerations in the selection of radionuclides for cancer therapy. In: Welch MJ, Redvanly CS (editors). Handbook of Radiopharmaceuticals, Radiochemistry and Applications. London: Wiley & Sons; 2003, pp. 767-793.